Flare risk after oral glucocorticoid bridging with methotrexate or intra‐articular bridging with triple therapy in early rheumatoid arthritis

Key Points

• This research aims to assess the risk of flares in early rheumatoid arthritis patients using different bridging therapies.
• Clinical trial with specific identifiers (EudraCT 2011-004720-35, ClinicalTrials.gov NCT01491815)
• Comparison of oral glucocorticoids with methotrexate versus intra-articular triple therapy
• Evaluation of flare incidents in participants during treatment.
• Identification of flare risk levels associated with each bridging method
• Comparison outcomes highlighting differences in flare rates
• Potential recommendations for improved management strategies.

Abstract